Diabetes Drug Linked To Increased Risk Of Bladder Cancer

by Colbert Cooper Hill Attorneys

The Food and Drug Administration (FDA) has issued a warning to patients taking the Type II diabetes drug, Actos®, about the increased risk of bladder cancer. A five-year study by the drug’s manufacturer, Takeda Pharmaceuticals, showed an increase in the risk of the cancer in patients who had taken the drug.

The research looked at 193,000 Type-II diabetes patients who were taking the drug for an average of two-years. Researchers stated that, “Compared to never being exposed to pioglitazone (Actos®), pioglitazone therapy lasting more than 12 months was associated with a 40 percent increase in risk for bladder cancer.”

Since the results of the study were made public, Actos has been pulled from European markets in Germany and France, and the FDA has warned doctors to refrain from starting new patients on the drug if they already have bladder cancer. Also, they are being told to use caution when prescribing the drug to patients who have been afflicted with bladder cancer in the past.

With no drug currently on the market to replace Actos®, doctors are being selective on who they prescribe the medication to and are choosing patients who have the highest insulin resistance.

An Actos® Drug Injury is a serious risk when beginning a regimen of this medication. That is why the Oklahoma Personal Injury Attorneys with J. Colbert Injury Lawyers suggest discussing other treatment options with your doctor before beginning to take Actos®.